The next generation of novel agents in development for aggressive B-cell lymphoma

Enrico Derenzini - The Next Generation of Novel Agents in Development for Aggressive B Cell LymphomaПодробнее

Multiple Myeloma Symposium: Future of Treatment | Dana-Farber Cancer InstituteПодробнее

Key novel agents for relapsed diffuse large B-cell lymphomaПодробнее

New Directions in Treating Multiple Myeloma in the Era of Novel AgentsПодробнее

Novel agents in development for the treatment of MCLПодробнее

Updates on novel agents in development for aggressive B-cell lymphomaПодробнее

Dr. Amengual on Novel Therapeutics for B-Cell LymphomaПодробнее

What is the most promising novel agent for the treatment of aggressive B-cell lymphoma?Подробнее

New Biological Insights and Novel Strategies in Aggressive B-cell LymphomaПодробнее

Novel agents for the treatment of Hodgkin lymphoma: brentuximab vedotin and nivolumabПодробнее

Next Questions: Aggressive B-Cell LymphomaПодробнее

Novel Immunotherapies (CAR T, Bispecifics, and ADCs) – Loretta Nastoupil, MDПодробнее

CNS invasion in B-cell lymphoma: a novel diagnostic and prognostic toolПодробнее

Novel Therapies in Aggressive Lymphoma & CAR T-cell TherapyПодробнее

Exciting advances in DLBCL: molecular characterization of subtypes & novel immunotherapeutic agentsПодробнее

Developing the novel Burkitt Lymphoma International Prognostic IndexПодробнее

New and Novel Agents for DLBCL: Bispecifics, CAR-T, and MoreПодробнее

How the standard of care for DLBCL is changing with the introduction of novel agentsПодробнее

The role of ibrutinib in DLBCL and the value of next-generation BTK inhibitorsПодробнее

Relapsed and Refractory Diffuse Large B-Cell LymphomaПодробнее

The Next Phase of Targeted Therapy in MCL and DLBCLПодробнее